Connect Biopharmaceuticals

orange pills and black inhaler
Biotech

Connect drug reduces COPD attacks 85%, misses a secondary goal

Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce respiratory attacks.
James Waldron Sep 30, 2026 8:54am
negative time concept

Connect not dismayed by Dupixent rival's ph. 2 asthma failure

Sep 15, 2026 9:55am
Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background

Connect’s Dupixent rival hits the mark in phase 3 eczema trial

Mar 30, 2026 9:32am
Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together

Connect reduces China workforce, mulls strategy for asthma drug

Sep 6, 2024 4:37am
Alps parachute rainbow mountains

J&J, Bayer, Santa Ana, Regenxbio and more—Chutes & Ladders

Jun 14, 2024 8:30am
Deal terminate tear up end deal scrap

Connect uncouples from Pfizer by scrapping eczema pact

Apr 17, 2024 6:38am